Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 233

1.

Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults.

Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C; Infectious Diseases Society of America.

Clin Infect Dis. 2003 Dec 1;37(11):1405-33. Epub 2003 Nov 3. No abstract available.

PMID:
14614663
2.

[Atypical pathogens of pneumonia acquired in ambulant persons].

Tuschy P, Lorenz J.

Dtsch Med Wochenschr. 2004 Mar 5;129(10):503-8. German. No abstract available.

PMID:
14986239
3.

[Therapy of non-nosocomial pneumonia].

Drömann D, Schaaf B.

MMW Fortschr Med. 2008 Jan 24;150(3-4):31-4; quiz 35. Review. German. No abstract available.

PMID:
18326476
4.

The science of selecting antimicrobials for community-acquired pneumonia (CAP).

File TM.

J Manag Care Pharm. 2009 Mar;15(2 Suppl):S5-11.

PMID:
19236135
5.

[Comparative analysis of guidelines for the treatment of community-acquired pneumonias].

Rodríguez de Castro F.

Arch Bronconeumol. 1999 Jun;35(6):253-6. Spanish. No abstract available.

PMID:
10410203
7.

In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure.

Jacobs MR.

Clin Infect Dis. 2002 Sep 1;35(5):565-9. Epub 2002 Aug 9. No abstract available.

PMID:
12173130
8.

The clinical efficacy of fluoroquinolone and macrolide combination therapy compared with single-agent therapy against community-acquired pneumonia caused by Legionella pneumophila.

Nakamura S, Yanagihara K, Izumikawa K, Seki M, Kakeya H, Yamamoto Y, Senjyu H, Saito A, Kohno S.

J Infect. 2009 Sep;59(3):222-4. doi: 10.1016/j.jinf.2009.06.008. Epub 2009 Jun 21. No abstract available.

PMID:
19592113
9.
10.

C-reactive protein for discriminating treatment failure from slow responding pneumonia.

Ruiz-González A, Falguera M, Porcel JM, Martínez-Alonso M, Cabezas P, Geijo P, Boixeda R, Dueñas C, Armengou A, Capdevila JA, Serrano R.

Eur J Intern Med. 2010 Dec;21(6):548-52. doi: 10.1016/j.ejim.2010.09.006.

PMID:
21111942
11.
12.

Prescription of macrolides in community-acquired pneumonia: science or art?

Rello J.

Chest. 1998 May;113(5):1155-8. No abstract available.

PMID:
9596285
13.

[Guidelines for treatment of pneumonia in intensive care units].

Emmi V.

Infez Med. 2005;Suppl:7-17. Review. Italian.

14.

[New quinolones for the treatment of community-acquired pneumonia--contra].

Egger M.

Dtsch Med Wochenschr. 2003 May 9;128(19):1071. German. No abstract available.

PMID:
12736860
15.

Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia.

Bhavnani SM, Forrest A, Hammel JP, Drusano GL, Rubino CM, Ambrose PG.

Diagn Microbiol Infect Dis. 2008 Sep;62(1):99-101. doi: 10.1016/j.diagmicrobio.2008.04.008. Epub 2008 Jun 25.

PMID:
18583085
17.

Scenario 1: a patient with mild community-acquired pneumonia--introduction to clinical trial design issues.

Gilbert DN.

Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S121-2. doi: 10.1086/591391.

PMID:
18986276
18.

[Antibiotic treatment for legionellosis].

Calbo E, Garau J.

Enferm Infecc Microbiol Clin. 2006 Jun-Jul;24(6):357-9. Spanish. No abstract available.

PMID:
16792935
19.

Empiric treatment of ambulatory community-acquired pneumonia: always include treatment for atypical agents.

Marrie TJ.

Infect Dis Clin North Am. 2004 Dec;18(4):829-41. Review.

PMID:
15555827
20.

Supplemental Content

Support Center